> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulated Companies Fear FDA Cuts Impact
- URL: https://www.fdaweb.com/regulated-companies-fear-fda-cuts-impact/
- Published: 2025-03-04T12:00:00.000Z
- Updated: 2026-09-14T14:54:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158763

“Dozens” of annual reports sent by drug companies to the Securities and Exchange Commission (SEC) warn of the impact of FDA staff and resource cuts, according to an online *Wired* post. The [post](https://www.wired.com/story/trump-fda-cuts-drug-development-delays/?ref=fdaweb.com) says that Xenon Pharmaceuticals told the SEC the Trump administration “has enacted several executive actions that could impose significant burdens on, or otherwise materially delay, FDA’s ability to engage in routine regulatory and oversight activities. If these executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively affected.”

The post notes that before new drugs can come to market, FDA has to conduct regular inspections and reviews, a process that it says can take years. “Many recent SEC filings say if FDA stops this work, these drugs simply can’t be released,” it adds.

Drug company Rezolute says a cut in agency funding would slow its work, and Rezolute’s business is dependent on FDA and the agency’s ability to timely respond to company drug development activities.

Some of the filings also discuss the impact of cuts to grants for drug development made through the National Institutes of Health. Others warned that the administration might overhaul existing drug regulations, which could cause additional time and money to achieve compliance with new requirements.

Verve Therapeutics said the executive order forbidding federal dollars from going to private companies with diversity, equity, and inclusion policies directly conflicts with the 2022 FDA Omnibus Reform Act that requires companies to enroll more diverse patient populations in clinical trials. Verve said it had to remove the drafted plans for diversifying clinical trials from its Web site and claims it could have “delays or difficulties” enrolling patients in clinical trials, the report says, potentially delaying or preventing certain drugs from ever receiving FDA approval.

Companies also mentioned that tariffs and cuts to Medicare and Medicaid could affect their business, *Wired* says.